Biogen Acquires Apellis for $5.6B
Biogen acquired Apellis in May 2026 to expand Biogen’s presence in immunology and rare diseases.
BioAdvance Capital Invests in Penn Life Sciences Startups
These investments will support the startups in further developing their treatments and technologies.
Dispatch Bio Initiates Clinical Trials for a New Type of Cancer Treatment
The technology is intended to overcome a key limitation of current CAR-T cell therapies by broadening the range of tumors that can be targeted and treated.
Biogen Reports Early Success from Apellis Acquisition
Since Biogen’s acquisition of Apellis in May 2026, the company’s C3 complement therapies, Syfovre® and Empaveli®, have generated a combined $128 million in revenues.
Nia Therapeutics Develops Breakthrough Device to Restore Memory
The device is based on technology developed at Penn by Dr. Kahana and Dr. Rizzuto.
Kira Pharmaceuticals to Merge with Jasper Therapeutics in a Deal Backed by $132M to Advance Immune Disease Pipeline
Jasper Therapeutics recently completed its merger with Kira Pharmaceuticals.
Vasowatch Seeks FDA Clearance for Postpartum Prediction Tools
The company is developing predictive software that transforms existing wearables into early-warning tools for postpartum hemorrhage.
New Clinical Data Move Cabaletta Closer to First Autoimmune CAR-T Approval
The company reported encouraging clinical data for its CAR T-cell therapy, RESE-CEL™.
Vivodyne and Opus Genetics Named Most Innovative Biotech Companies of 2026 by Fast Company
The companies are spun out of Penn Engineering and Penn Medicine, respectively.